Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal StudyBenzinga • 11/25/24
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire • 11/15/24
Scholar Rock Reports Third Quarter 2024 Financial Results and Highlights Business ProgressBusiness Wire • 11/12/24
Scholar Rock Announces New Preclinical Data for SRK-439 Showing Significant Lean Mass Increase and Enhanced Fat Mass Loss with MetforminBusiness Wire • 11/04/24
Scholar Rock to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024Business Wire • 11/01/24
Scholar Rock to Present New Clinical and Biomarker Data from the Phase 1 DRAGON Trial at the SITC 39th Annual MeetingBusiness Wire • 10/31/24
Scholar Rock Announces Closing of Full Exercise of Option to Purchase Additional Shares in Public OfferingBusiness Wire • 10/22/24
Should You Buy Scholar Rock Holding Corporation (SRRK) After Golden Cross?Zacks Investment Research • 10/21/24
Scholar Rock Announces Pricing of Upsized $300 Million Public Offering of Common Stock and Pre-Funded WarrantsBusiness Wire • 10/09/24
SRRK Stock Soars as Muscle Disease Drug Meets Phase III Study GoalZacks Investment Research • 10/08/24
Scholar Rock Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsBusiness Wire • 10/07/24
Dow Jones, S&P 500 fall amid rising oil prices; Scholar Rock jumps 300%, Apple and insurance stocks dipInvezz • 10/07/24
Scholar Rock's Muscle Wasting Drug Excels In Pivotal Trial, Plans FDA Submission Next YearBenzinga • 10/07/24
Scholar Rock Catapults By Triple Digits On Final-Phase Win In Spinal Muscular AtrophyInvestors Business Daily • 10/07/24
Scholar Rock's stock soars more than 200% on positive trial of treatment for spinal muscular atrophyMarket Watch • 10/07/24
Scholar Rock Reports Apitegromab Meets Primary Endpoint in Phase 3 SAPPHIRE Study in Patients with Spinal Muscular Atrophy (SMA)Business Wire • 10/07/24
Scholar Rock Completes Enrollment in Phase 2 EMBRAZE Proof-of-Concept Trial of Apitegromab in ObesityBusiness Wire • 09/10/24